Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease (PREVENT)
Sudden cardiac death (SCD) is one of the leading causes of death in developed countries. These deaths (more than 5,000 per year in France) are due to hereditary arrhythmias or cardiomyopathies. Early diagnosis of SCD is often achieved through family screening, but the main challenge is to stratify the risk of SCD in these patients. Indeed, prevention of SCD relies mainly on the implantation of an automatic defibrillator. The challenge is to identify patients who will develop SCD and avoid implanting an implantable cardioverter defibrillator (ICD) in patients who will never develop arrhythmias but who will face complications related to the ICD (inappropriate shocks, infection, lead failure), leading to a reduced quality of life and significant costs for the healthcare system. However, there is a lack of relevant clinical and biological markers for risk stratification, which rules out any possibility of preventive screening. Most of the clinical and ECG (electrocardiogram) parameters identifying an increased risk of SCD have not been reproduced in replication studies.
In this project, the investigator will develop a data processing and analysis pipeline using artificial intelligence methods to assess the individual risk of serious arrhythmic events or heart failure in patients with hereditary arrhythmic diseases or cardiomyopathies through the automated processing of multimodal data (clinical data, electrocardiogram (ECG), imaging (echocardiography, MRI magnetic resonance imaging), genetic data, biomarkers).
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The eligibility of patients (index cases and related cases) for the study will be determined during a cardiology consultation or day hospitalisation, carried out as part of routine care.
The investigator undertakes to obtain the person's free, informed and express consent, collected in writing, after providing them with oral and written information on the protocol and allowing them sufficient time to reflect. In the case of a minor patient, the investigator undertakes to inform the minor patient and their legal representatives orally and in writing and to obtain the minor's assent, i.e. their oral or written agreement depending on their age, and the written consent of their legal representatives.
Specific acts for research:
- Collection of two additional EDTA tubes (2 x 5 ml) during a blood test carried out as part of routine care, except for minors under the age of 4, for whom a saliva sample will be offered instead.
- Collection of one dry tube (5 ml) during a blood test carried out as part of routine care for biomarker analysis and only for adult patients.
Clinical data will be collected in a parameterised and secure eCRF (electronic Case Report Form).
Patients will be followed in the routine care for maximum 10 years. Arrhythmias, heart failure and sudden cardiac death will be collected during follow-up.
A data processing and analysis pipeline using artificial intelligence methods to assess the individual risk of serious arrhythmic events or heart failure in patients with hereditary arrhythmic diseases or cardiomyopathies through the automated processing of multimodal data (clinical data, electrocardiogram (ECG), imaging (echocardiography, MRI magnetic resonance imaging), genetic data, biomarkers) will be developped.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Vincent Probst, PU-PH
- Phone Number: 02 40 16 56 99
- Email: vincent.probst@chu-nantes.fr
Study Contact Backup
- Name: Aurélie Thollet
- Email: aurelie.thollet@chu-nantes.fr
Study Locations
-
-
-
Bordeaux, France
- Not yet recruiting
- CHU de Bordeaux
-
Contact:
- SACHER Frédéric
- Email: frederic.sacher@chubordeaux.fr
-
Brest, France
- Not yet recruiting
- CHU de Brest
-
Contact:
- MANSOURATI Jacques
- Email: jacques.mansourati@chu-brest.fr
-
Clermont-Ferrand, France
- Not yet recruiting
- CHU de Clermont-Ferrand
-
Contact:
- ESCHALIER Romain
- Email: reschalier@chu-clermontferrand.fr
-
Dijon, France
- Not yet recruiting
- CHU de Dijon
-
Contact:
- LAURENT Gabriel
- Email: gabriel.laurent@chu-dijon.fr
-
La Rochelle, France
- Not yet recruiting
- CHU de La Rochelle
-
Contact:
- AL-ARNAOUT Alain
- Email: alain.alarnaout@ght-atlantique17.fr
-
Limoges, France
- Not yet recruiting
- CHU de Limoges
-
Contact:
- GUY-MOYAT Benoît
- Email: benoit.guy-moyat@chu-limoges.fr
-
Montpellier, France
- Not yet recruiting
- CHU de Montpellier
-
Contact:
- PASQUIE Jean-Luc
- Email: jl-pasquie@chu-montpellier.fr
-
Nantes, France, 44093
- Recruiting
- CHU de Nantes
-
Contact:
- Probst Vincent, PUPH
- Phone Number: +33 240165699
- Email: vincent.probst@chu-nantes.fr
-
Poitiers, France
- Not yet recruiting
- CHU De Poitiers
-
Contact:
- GARCIA Rodrigue
- Email: rodrigue.garcia@chu-poitiers.fr
-
Rennes, France
- Not yet recruiting
- CHU de Rennes
-
Contact:
- BEHAR Nathalie
- Email: nathalie.behar@chu-rennes.fr
-
Strasbourg, France
- Not yet recruiting
- CHU de Strasbourg
-
Contact:
- JESEL Laurence
- Email: laurence.jesel@chru-strasbourg.fr
-
Toulouse, France
- Not yet recruiting
- CHU de Toulouse
-
Contact:
- MAURY Philippe
- Email: maury.p@chu-toulouse.fr
-
Tours, France
- Not yet recruiting
- CHU de Tours
-
Contact:
- PIERRE Bertrand
- Email: b.pierre@chu-tours.fr
-
-
-
-
-
Fort-de-France, Martinique
- Not yet recruiting
- CHU de la Martinique
-
Contact:
- DEMONIERE Fabrice
- Email: fabrice.demoniere@chu-martinique.fr
-
-
-
-
-
Saint-Pierre, Reunion
- Not yet recruiting
- CHU de la Réunion
-
Contact:
- WIART François
- Email: francois.wiart@chu-reunion.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria :
I. hereditary heart disease II. All relatives of patients III. Patients referred to the reference centre for suspected hereditary rhythm disorders or cardiomyopathies IV. Written consent V. social security scheme
Exclusion Criteria :
I. Patients participating in a therapeutic trial that may interfere with the research results II. Patients under guardianship or curatorship.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Arrhythmic and heart failure risk stratification
Time Frame: 5, 8 and 10 years
|
to assess the arrhythmic risk and/or risk of heart failure in patients with hereditary heart disease at 5, 8 and 10 years, using a model combining clinical, electrocardiographic, imaging, genetic and biomarker data.
|
5, 8 and 10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demographics data
Time Frame: 5, 8 and 10 years
|
Determine the risk of arrhythmia and/or heart failure based on demographics data
|
5, 8 and 10 years
|
|
Diagnosis of Brugada syndrome
Time Frame: 5 years
|
Evaluate the diagnostic performance of the model combining clinical, electrocardiographic, genetic and biomarker data for the identification of Brugada syndrome.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- RC25_0107
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.